Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Pending | |||
| Ferinject | ferric carboxymaltose | Iron deficiency anemia | Pending | |||
| Vabysmo | faricimab | Retinal vein occlusion | Pending | |||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Pending | |||
| Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Pending |
Last Updated : May 2, 2024